Anew Medical Inc. (KLTOW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation
Klotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation from the US Food and Drug Administration (FDA), The news sent Klotho's shares higher in early trade on Thursday, up 5.8% at about $1.45. ALS is a rare, progressive neurodegenerative disease commonly known as Lou Gehrig's disease.
Anew Medical Inc. (KLTOW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anew Medical Inc. ever had a stock split?
Anew Medical Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joseph Sinkule CEO | NASDAQ (CM) Exchange | 49876K111 CUSIP |
| US Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Klotho Neurosciences, Inc. is a biopharmaceutical company dedicated to the development of therapeutic solutions for multifaceted health issues, including cancer, cardiovascular diseases, and neurodegenerative disorders. Founded under the name Anew Medical, Inc., the company underwent a rebranding to Klotho Neurosciences, Inc. in September 2024, signaling a refined focus on leveraging cutting-edge gene therapy to combat neurological diseases. With its headquarters in Omaha, Nebraska, Klotho Neurosciences is at the forefront of creating innovative treatments with the potential to drastically improve patient outcomes in some of the most challenging areas of medicine today.
Products and Services
- AMI-101 for Alzheimer's Disease
As a leading product candidate of Klotho Neurosciences, AMI-101 is a gene therapy solution crafted for the treatment or prevention of Alzheimer's disease. Alzheimer's disease, a degenerative brain disorder, is the most common cause of dementia and represents a significant challenge in the medical community due to its complex nature and lack of curative treatments. AMI-101 aims to address this gap by targeting underlying genetic mechanisms believed to be responsible for the disease's progression, offering hope for not only halting but possibly reversing some of the cognitive declines associated with Alzheimer's.
- AMI-202 for Amyotrophic Lateral Sclerosis (ALS)
AMI-202, another pioneering gene therapy candidate from Klotho Neurosciences, is designed to treat and prevent amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a fatal neurodegenerative disorder characterized by the deterioration of motor neurons, leading to muscle weakness and eventually, paralysis. The development of AMI-202 represents a significant leap forward in ALS treatment, focusing on the genetic alterations that contribute to the disease's development. This approach offers a new avenue for potentially slowing the disease's progression or preventing its onset, providing much-needed hope to patients and families affected by ALS.
Contact Information
